Brokerages Set Geron Corporation (NASDAQ:GERN) Price Target at $4.19

Geron Corporation (NASDAQ:GERN) has earned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $4.1875.

Separately, The Goldman Sachs Group initiated coverage on shares of Geron in a research report on Thursday, July 10th. They issued a “sell” rating and a $1.00 price objective for the company.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Frisch Financial Group Inc. grew its position in shares of Geron by 84.3% in the 1st quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 8,700 shares during the period. StoneCrest Wealth Management Inc. bought a new position in shares of Geron in the 2nd quarter valued at about $35,000. Integrated Wealth Concepts LLC bought a new position in shares of Geron in the 4th quarter valued at about $36,000. Savant Capital LLC grew its position in shares of Geron by 73.8% in the 2nd quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 11,074 shares during the period. Finally, Summit Financial Strategies Inc. bought a new position in shares of Geron in the 2nd quarter valued at about $38,000. Institutional investors own 73.71% of the company’s stock.

Geron Stock Up 1.4%

Geron stock opened at $1.40 on Wednesday. The company has a market cap of $893.22 million, a P/E ratio of -10.77 and a beta of 0.63. Geron has a 1-year low of $1.09 and a 1-year high of $4.83. The company has a fifty day simple moving average of $1.34 and a 200 day simple moving average of $1.47. The company has a current ratio of 7.87, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46.

Geron (NASDAQ:GERN) last released its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Geron had a negative net margin of 53.52% and a negative return on equity of 31.37%. The business had revenue of $49.04 million during the quarter, compared to the consensus estimate of $47.30 million. During the same quarter last year, the firm earned ($0.10) earnings per share. The firm’s revenue for the quarter was up 5455.6% compared to the same quarter last year. Research analysts anticipate that Geron will post -0.25 earnings per share for the current fiscal year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.